시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 신경통 치료 시장 보고서(2025년)
Neuralgia Treatment Global Market Report 2025
상품코드 : 1693359
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,496,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,390,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,284,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

신경통 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 31억 3,000만 달러에 달할 것으로 예상되며, CAGR은 6.4%에 달할 것으로 예상됩니다. 예측 기간의 성장은 인구 고령화, 새로운 치료법, 당뇨병 유병률 증가, 높은 의료비 지출에 기인합니다. 예측 기간 동안 주요 동향으로는 통증 관리의 발전, 혁신적인 제품, 디지털 헬스 통합, 새로운 약물전달 시스템 개발 등이 있습니다.

당뇨병과 같은 만성질환의 유병률 증가는 신경통 치료 시장의 확대를 촉진할 것으로 예상됩니다. 만성질환은 지속적인 치료가 필요하거나 일상적인 활동을 제한하거나 두 가지 모두를 수반하는 장기적인 질환입니다. 당뇨병은 혈당 상승을 특징으로 하는 대사성 질환으로, 이러한 질환 중 하나입니다. 신경통 치료는 당뇨병 환자에게 흔히 나타나는 신경장애의 일종인 당뇨병성 신경장애의 관리에 도움이 됩니다. 예를 들어, 스위스에 본부를 둔 유엔 전문기구인 세계보건기구(WHO)는 2023년 9월 비감염성 질환(NCDs)으로 인한 사망자의 74%에 해당하는 4,100만 명이 매년 전 세계에서 사망하고 있다고 보고했습니다. 이에 따라 당뇨병을 포함한 만성질환의 유병률 증가가 신경통 치료 시장의 성장에 박차를 가하고 있습니다.

수술 건수의 증가는 신경통 치료 시장의 성장을 촉진할 것으로 예상됩니다. 외과적 시술은 절개가 필요하거나 최소침습 기술을 사용하여 신체의 조직이나 장기에 접근하여 치료하는 의료 개입을 수반합니다. 이러한 시술은 비수술적 치료가 효과적이지 않거나 특정 해부학적 문제를 외과적으로 해결할 수 있는 경우 환자에게 선택권을 제공함으로써 신경통 치료 시장 확대에 기여하고 있습니다. 예를 들어, 2024년 2월 미국 정부 기관인 National Healthcare Statistics에 따르면, 2022년 가장 많이 시행된 수술은 백내장 수술로 39,347건이며, 이 중 98.3%가 당일 수술로 이루어졌습니다. 이어 제왕절개 20,537건, 인공고관절 치환술 12,830건으로 대부분 입원 수술이었습니다. 이처럼 수술 건수의 증가가 신경통 치료 시장의 성장을 견인할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Neuralgia treatment involves addressing a medical condition characterized by persistent nerve-related pain, which can result from injury, infection, or underlying medical issues. This treatment aims to effectively manage symptoms, slow the progression of neuralgia, and prevent potential complications.

Neuralgia treatment primarily falls into two categories drug-based therapies and surgical interventions. Drug-based treatment involves the use of medications to manage, alleviate, or even cure various medical conditions and diseases, including diabetic neuropathy, intercostal neuralgia, occipital neuralgia, peripheral neuralgia, and postherpetic neuralgia. These medications are accessible through various distribution channels such as drug stores, hospital pharmacies, online pharmacies, and retail pharmacies. They are utilized in diverse healthcare settings, including hospitals, clinics, ambulatory surgery centers, and other medical facilities.

The neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides neuralgia treatment market statistics, including neuralgia treatment industry global market size, regional shares, competitors with a neuralgia treatment market share, detailed neuralgia treatment market segments, market trends and opportunities and any further data you may need to thrive in the neuralgia treatment industry. This neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuralgia treatment market size has grown strongly in recent years. It will grow from $2.3 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to rising prevalence of neuralgia, neuropathic pain awareness, rise in chronic pain conditions, presence of high disposable income, government initiatives.

The neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging population, emerging therapies, increasing incidences of diabetes, high healthcare expenditure. Major trends in the forecast period include advancements in pain management, innovative products, digital health integration, development of new drug delivery systems.

The growing prevalence of chronic diseases, such as diabetes, is expected to drive the expansion of the neuralgia treatment market. Chronic diseases are long-term conditions that require ongoing medical care, limit daily activities, or both. Diabetes, a metabolic disorder marked by elevated blood glucose levels, is one such condition. Neuralgia treatments can help manage diabetic neuropathy, a type of nerve damage commonly seen in individuals with diabetes. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that 41 million deaths, or 74% of those caused by non-communicable diseases (NCDs), occur globally each year. As a result, the increasing prevalence of chronic diseases, including diabetes, is fueling the growth of the neuralgia treatment market.

The expected rise in the number of surgical procedures is anticipated to drive the growth of the neuralgia treatment market. Surgical procedures involve medical interventions that either require incisions or utilize minimally invasive techniques to access and treat tissues or organs within the body. These procedures contribute to the expansion of the neuralgia treatment market by providing options for patients when non-surgical treatments are ineffective or when a specific anatomical issue can be surgically addressed. For example, in February 2024, the National Healthcare Statistics, a US-based government agency, reported that cataract surgery was the most commonly performed procedure in 2022, with 39,347 cases, 98.3% of which were day cases. This was followed by 20,537 caesarean sections and 12,830 hip replacements, most of which were inpatient procedures. Thus, the increasing number of surgical procedures is expected to drive the growth of the neuralgia treatment market.

Major players in the neuralgia treatment market are dedicated to the development of cutting-edge products and solutions to maintain their competitive edge in the industry. As an illustration, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, the world's first non-live recombinant subunit vaccine. This vaccine is specifically designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and above, administered intramuscularly in two doses. Shingrix leverages the antigen glycoprotein E along with the adjuvant system AS01B to generate a potent and long-lasting immune response, countering age-related immune system deterioration. Clinical trials have demonstrated its remarkable 97% effectiveness in preventing shingles in adults, while also effectively guarding against post-herpetic neuralgia, a painful complication of shingles.

In November 2022, Kriya Therapeutics Inc., a gene therapy company based in the United States, completed the acquisition of Redpin Therapeutics Inc. The specific financial details of the transaction were not disclosed. This strategic acquisition is poised to enhance Kriya Therapeutics Inc.'s gene therapy portfolio for addressing neurological disorders, encompassing conditions like epilepsy, trigeminal neuralgia, and Parkinson's disease. Redpin Therapeutics Inc., also based in the United States, is a biotechnology company with a strong track record in effectively treating a range of neurological disorders, including neuralgia.

Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Horizon Therapeutics, Purdue Pharma, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals, Tonix Pharmaceuticals.

North America was the largest region in the neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuralgia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuralgia treatment market consists of revenues earned by entities by providing blood tests, magnetic resonance imaging (MRI), nerve conduction velocity tests, physical therapies and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuralgia treatment market also includes sales of anticonvulsant medications, pain relievers, antidepressants and antiseizure medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuralgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuralgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for neuralgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuralgia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Neuralgia Treatment Market Characteristics

3. Neuralgia Treatment Market Trends And Strategies

4. Neuralgia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neuralgia Treatment Growth Analysis And Strategic Analysis Framework

6. Neuralgia Treatment Market Segmentation

7. Neuralgia Treatment Market Regional And Country Analysis

8. Asia-Pacific Neuralgia Treatment Market

9. China Neuralgia Treatment Market

10. India Neuralgia Treatment Market

11. Japan Neuralgia Treatment Market

12. Australia Neuralgia Treatment Market

13. Indonesia Neuralgia Treatment Market

14. South Korea Neuralgia Treatment Market

15. Western Europe Neuralgia Treatment Market

16. UK Neuralgia Treatment Market

17. Germany Neuralgia Treatment Market

18. France Neuralgia Treatment Market

19. Italy Neuralgia Treatment Market

20. Spain Neuralgia Treatment Market

21. Eastern Europe Neuralgia Treatment Market

22. Russia Neuralgia Treatment Market

23. North America Neuralgia Treatment Market

24. USA Neuralgia Treatment Market

25. Canada Neuralgia Treatment Market

26. South America Neuralgia Treatment Market

27. Brazil Neuralgia Treatment Market

28. Middle East Neuralgia Treatment Market

29. Africa Neuralgia Treatment Market

30. Neuralgia Treatment Market Competitive Landscape And Company Profiles

31. Neuralgia Treatment Market Other Major And Innovative Companies

32. Global Neuralgia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuralgia Treatment Market

34. Recent Developments In The Neuralgia Treatment Market

35. Neuralgia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기